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Abstract
Anti-neutrophil cytoplasmic antibody vasculitis is a systemic autoimmune disease with glomerulonephritis and
pulmonary haemorrhage as major clinical manifestations. The name reflects the presence of autoantibodies to
myeloperoxidase and proteinase-3, which bind to both neutrophils and monocytes. Evidence of the pathogenicity
of these autoantibodies is provided by the observation that injection of anti-myeloperoxidase antibodies into
mice causes a pauci-immune focal segmental necrotizing glomerulonephritis which is histologically similar to the
changes seen on renal biopsy in patients. Previous studies in this model have implicated the alternative pathway
of complement activation and the anaphylatoxin C5a. Despite this progress, the factors that initiate complement
activation have not been defined. In addition, the relative importance of bone marrow-derived and circulating
C5 is not known. This is of interest given the recently identified roles for complement within leukocytes. We
induced anti-myeloperoxidase vasculitis in mice and confirmed a role for complement activation by demonstrating
protection in C3-deficient mice. We showed that neither MASP-2- nor properdin-deficient mice were protected,
suggesting that alternative pathway activation does not require properdin or the lectin pathway. We induced
disease in bone marrow chimaeric mice and found that circulating and not bone marrow-derived C5 was required
for disease. We have therefore excluded properdin and the lectin pathway as initiators of complement activation
and this means that future work should be directed at other potential factors within diseased tissue. In addition,
in view of our finding that circulating and not bone marrow-derived C5 mediates disease, therapies that decrease
hepatic C5 secretion may be considered as an alternative to those that target C5 and C5a.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Anti-neutrophil cytoplasmic antibody (ANCA) vasculi-
tis is a systemic disease causing crescentic glomeru-
lonephritis and pulmonary haemorrhage. Other clinical
features include disease affecting skin, the nervous sys-
tem, and upper airways [1]. The name ANCA vasculitis
reflects the fact that it is characterized by autoantibod-
ies against neutrophils [2,3], although they also bind
to monocytes. The antigenic targets of the autoantibod-
ies have been identified as myeloperoxidase (MPO) or
proteinase 3 (PR3) [4,5] and these enzymes are indeed
found within granules in both neutrophils and mono-
cytes. In addition to their clinical utility, the suggestion
that these autoantibodies were pathogenic came from in
vitro studies in which IgG from patients with anti-MPO
or anti-PR3 antibodies activates neutrophils to undergo
respiratory burst and degranulation [6]. Many subse-
quent studies have supported this observation (reviewed
in ref 7). However, it was not until 2002 that in vivo
evidence of pathogenicity was obtained. Anti-MPO anti-
bodies raised in MPO-deficient mice were shown to
cause a focal necrotizing crescentic glomerulonephritis
when injected into wild-type mice [8].
In this murine anti-MPO model, both the histological
and the clinical features of glomerulonephritis closely
mirror the situation in patients. The crescentic glomeru-
lonephritis is focal and segmental, affecting segments of
some glomeruli and not others, and also shows necro-
sis with a lack of immune deposits. All of these features
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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recapitulate characteristics of the histology seen in clin-
ical renal biopsy samples. Furthermore, proteinuria is
relatively mild and not in the nephrotic range, as is the
case for patients. In addition to providing evidence of
pathogenicity, the murine anti-MPO model has become
established as a preclinical model, which is useful for
understanding mechanisms and developing therapies in
ANCA vasculitis. Previous work using this model has
suggested that the alternative pathway (AP) is important,
as mice deficient in factor B, but not C4, were protected
[9]. C5-deficient mice are also protected, and treatment
with an anti-C5 monoclonal antibody inhibited disease
[10], providing evidence of a role for C5. Furthermore,
MPO-deficient mice immunized with MPO and trans-
planted with bone marrow from C5a receptor-deficient
mice were protected from disease, compared with mice
that received wild-type bone marrow, suggesting that the
anaphylatoxin C5a is the key mediator [11]. This work
has recently been extended with evidence of therapeutic
efficacy for the C5a receptor antagonist CCX168 inmice
in which the C5a receptor has been replaced with the
human equivalent [12]. In addition, disease was exac-
erbated in mice defective in the second C5a receptor
C5L2 [12]. This work in the anti-MPO model has led
to clinical trials in which CCX168 is currently being
tested in patients with ANCA vasculitis (trial registra-
tions NCT01363388 and NCT02222155).
The trigger leading to AP activation has not been
identified and this raises an important question given
the interest in therapies targeting the complement path-
way in ANCA vasculitis. Properdin is established as
a key stabilizer of the AP but recent data have also
shown that it may bind to apoptotic cells and initiate
AP activation [13,14]. Another candidate for initiating
AP activation is the lectin pathway. Recent work has
shown that C4 is not required for lectin pathway activa-
tion [15], and so we considered that the lectin pathway
may be important in initiating complement activation,
with subsequent amplification by the AP. Therefore, in
order to explore the initial events leading to comple-
ment activation, we studied both properdin-deficient and
MBL-associated serine protease 2 (MASP-2)-deficient
mice in the anti-MPO model. Finally, in view of the
recently discovered importance of intracellular comple-
ment components [16–21], we examined the relative
importance of bone marrow-derived and circulating C5
in anti-MPO vasculitis.
Materials and methods
Mice
Wild-type C57BL/6 mice were from Harlan
(Bicester, Oxon, UK). MASP-2- [15], C3- [22],
properdin- [23], and C5-deficient mice [24] have been
previously described. We confirmed that mice were
C5-deficient by testing serum using a mouse C5 ELISA
duoset (R&D Systems, Abingdon, Oxfordshire, UK).
MASP-2-deficient mice were provided by Omeros Corp
(Seattle, WA, USA). Properdin-deficient mice were
backcrossed more than 16 generations, and all others
were backcrossed at least ten generations to C57BL/6.
MASP-2×C3-deficient mice were generated, with
homozygosity for the disrupted MASP-2 allele con-
firmed by PCR and the absence of serum C3 confirmed
by ELISA [25]. Bone marrow chimaeras were made
as described previously [26]. A parallel cohort of chi-
maeras was made between wild-type C57BL/6 mice and
C57BL/6 mice congenic for CD45.1 (B6.SJL-Ptprca
Pepcb/BoyJ). Chimaerism was determined by flow
cytometry for CD45.2 on whole blood with clone 104
from eBioscience (Hatfield, UK), and chimaerism was
more than 90% in all cases (n= 7). Animal experiments
complied with the Animals (Scientific Procedures) Act
1986 and Home Office and local regulations.
Induction of anti-MPO crescentic
glomerulonephritis
Anti-MPO antibody was generated and glomeru-
lonephritis induced as previously described [27], with
minor modifications. Day 0 denotes the day that 2mg
of anti-MPO IgG was injected. In all experiments apart
from those with C5 bone marrow chimaeras, 30 μg of
pegylated GCSF (Neulasta, Amgen, Cambridge) was
given subcutaneously on days−8,−4, 0 and 4, and 10 μg
of LPS (from E. coli serotype 0111 B4; Enzo Life Sci-
ences, Exeter, UK) was given intraperitoneally on days
0 and 3. In the C5 bone marrow chimaera experiment,
anti-MPO IgG was given intraperitoneally and 30 μg
of pegylated GCSF was given subcutaneously on days
−4 and 0. 2.5 μg of LPS was given intraperitoneally on
day 0 only. Blood was taken from the saphenous vein
on day −1 to measure circulating neutrophils by flow
cytometry [27] or baseline serum creatinine by mass
spectrometry [28]. For the experiments with MASP-2-
and properdin-deficient mice, metabolic cages were
used to collect urine in the last 24 h of the experiment.
In other experiments, spot urine was taken on day −1
and on day 6 for the urine albumin creatinine ratio. In
all experiments, mice were killed on day 7.
Assessment of disease
Urine creatinine was measured using a commer-
cial creatinase assay (Diazyme, Dresden, Germany)
based on the manufacturer’s instructions, with a
standard curve generated for all assays. Histology,
serum creatinine and urine albumin analysis were as
described previously [27,28]. Crescent formation was
defined as at least two layers of non-epithelial cells
in Bowman’s space. Immunofluorescence staining for
MBL and C3 was performed using tissue fixed with
phosphate–lysine–periodate prior to freezing and sec-
tioning. For MBL, clone 16A8 (Hycult Biotechnology,
Uden, The Netherlands) was used and for C3, clone
RMC11H9 (Cedarlane, Burlington, Ontario, Canada).
Detection was with DyLight 488 mouse anti-rat IgG
(Jackson ImmunoResearch Laboratories, West Grove,
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PA, USA). Sections stained with secondary antibody
only were included as controls and were negative
(supplementary material, Figure S1). Fibrin staining
was produced using a FITC-labelled rabbit anti-human
fibrinogen/fibrin antibody (Dako, Cambridge, UK)
which cross-reacted with mouse fibrinogen/fibrin. For
C3, glomerular fluorescence intensity was quantified
using ImageJ software (NIH, USA). For MBL and fibrin
quantification, the software used was Cell (Olympus,
Southend-on-Sea, UK). A minimum of 20 glomeruli
per sample were included in all cases.
Coagulation assays
Blood (900 μl) was taken by intracardiac puncture
under terminal anaesthesia into a 1ml syringe contain-
ing 100 μl of 3.2% trisodium citrate (Sigma, Poole,
UK). Plasma was double spun (800 g), aliquoted,
and frozen until analysed. Thrombin generation was
monitored with a Fluoroskan Ascent Thrombinoscope
(Thermo Electron Corporation, Paisley, UK) and
Thrombinoscope software version 5. Samples were run
at a dilution of 1 in 3 and at 33 ∘C [29]. Clauss fibrinogen
was measured using the ACL300R analyser, and using
the HemosIL Fibrinogen-C reagent byWerfenUK (War-
rington, Cheshire, UK). Prothrombin fragment 1.2 was
measured by ELISA using an Enzygost F1+ 2Micro kit
from Sysmex UK Ltd (Wymbush, Milton Keynes, UK).
Neutrophil activation
Human neutrophils were isolated from healthy donors
(ethical approval NRES committee London – London
Bridge 09/H084/72) as previously described [27] and
primed with 2 ng/ml TNFα for 15min at 37 ∘C and
stimulated with antibody or fMLP for 60min. Mono-
clonal mouse IgG1 anti-MPO was clone 266.6K2 (IQ
Products Company, Houston, TX, USA), anti-PR3 was
clone WGM2 (Hycult Biotech, Uden, Netherlands),
and control mouse IgG1 was anti-TNP clone 107.3
(BD Biosciences, Oxford, UK). Monoclonals were
used at 5 μg/ml and fMLP at 100 ng/ml. The reaction
was stopped with a 30-fold volume of cold HBSS with
HEPES (Sigma). The C5 antibody was a rabbit poly-
clonal and C5a was clone 2952 (PE conjugate), both
from Abcam (Cambridge, UK). The secondary antibody
for C5 staining was goat anti-rabbit IgG (Alexa Fluor
488 conjugate) from Invitrogen (Carlsbad, CA, USA).
Cells were permeabilized with cytofix/cytoperm (BD
Biosciences). A FACS Canto flow cytometer (BD Bio-
sciences) and FACsDIVA software (BD Biosciences)
was used. C5a was assayed using cytometric beads (BD
Biosciences).
Statistics
GraphPad Prism version 5 (GraphPad Software Inc, La
Jolla, CA, USA), with Student’s t-test, was used where
two groups were compared. If more than two groups
were compared, a one-way ANOVA with Tukey’s
post-test was used. Some data were logarithmically
transformed before analysis if the variances of the
groups were significantly different.
Results
Properdin-deficient mice are not protected
in anti-MPO vasculitis
Because previous work had shown that the AP was
important in anti-MPO vasculitis, we wondered if
properdin was essential and perhaps could initi-
ate complement activation. We therefore studied
properdin-deficient mice with the aim of confirming
and extending our understanding of AP activation in
anti-MPO vasculitis. We found that both histological
and functional parameters of disease severity were sim-
ilar to wild types as shown in Figure 1A–E. Figure 1F
shows representative histology and CD68+macrophage
staining. Circulating neutrophil counts were the same
in both groups after GCSF treatment (supplementary
material, Table S1). These data showed that properdin is
not essential for AP activation in anti-MPO vasculitis,
and that the trigger for AP activation involves other
mechanisms.
MASP-2-deficient mice develop increased disease
in the anti-MPO vasculitis model
Since properdin was not required, we considered that
lectin pathway activation may initiate complement
activation independently of C4 [15]. This might then be
followed by amplification via the AP. We first induced
crescentic glomerulonephritis in mice by injecting
anti-MPO antibody and compared disease severity
at day 7 in MASP-2-deficient mice with wild types.
MASP-2-deficient mice had significantly more disease,
both functionally and histologically, than wild types, as
shown in Figure 2. MASP-2-deficient mice had more
glomerular crescents, more haematuria, and a higher
serum creatinine. We did not find a difference in albu-
minuria, and the trend towards increased glomerular
CD68+ macrophages did not reach significance. These
findings were not due to differences in the clearance
of anti-MPO antibody as levels were the same at the
end of the experiment (supplementary material, Figure
S2). They were also not due to differences in circu-
lating neutrophil counts following GCSF treatment
(supplementary material, Table S1). Overall, these
data demonstrated that MASP-2-deficient mice are not
protected from crescentic glomerulonephritis induced
by anti-MPO antibodies and are in fact predisposed
to more severe disease. Both properdin and the lectin
pathway are therefore excluded as the initiator of AP
activation in anti-MPO vasculitis.
MASP-2/C3 double-deficient- and C3-deficient
mice are protected from disease
The reason for the increased disease severity in
MASP-2-deficient mice was not clear; it was not
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 61–71
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Figure 1. Histological and functional readouts of anti-MPO vasculitis in properdin-deficient mice compared with wild types. (A, B)
Histological readouts of glomerular crescents and glomerular CD68+ macrophages. (C–E) Functional readouts of serum creatinine,
albuminuria, and haematuria. Each symbol represents a separate mouse. (F) Representative renal histology showing periodic acid Schiff
(PAS)-stained sections and immunofluorescence staining for CD68+ macrophages from mice with anti-MPO vasculitis. Scale bars= 20 μm.
Error bars are mean± SEM.
due to a difference in anti-MPO antibody remaining in
the circulation at day 7 (supplementary material, Figure
S2). We therefore sought to examine if the increased
disease depended on complement activation and com-
pared disease in wild-type mice and mice deficient in
both C3 and MASP-2 with mice deficient in C3. As
shown in Figure 3, there was very mild disease in both
C3-deficient and MASP-2/C3 double-deficient mice.
There was no difference between these groups in any
of the histological or functional parameters examined,
and both had significantly less disease than wild-type
mice. This meant that we were unable to determine
if the increase in disease, in MASP-2-deficient mice
compared with wild types, depended on C3 activation
with this experiment. However, circulating C3 levels in
untreated MASP-2-deficient mice did not differ from
wild types (supplementary material, Figure S3). In addi-
tion, glomerular deposition of C3 in MASP-2-deficient
mice with anti-MPO vasculitis was similar to that in
wild-type mice (supplementary material, Figure S3).
This suggested that there was no major dysregula-
tion of the AP of complement in MASP-2-deficient
mice. Figure 4 shows representative histology and
immunofluorescence staining for CD68+ macrophages
in wild-type, MASP-2-deficient, MASP-2/C3-deficient,
and C3-deficient mice. Also shown in Figure 4 is stain-
ing for MBL, which demonstrates deposition of MBL,
and by inference MASP-2, within diseased glomeruli.
There was no difference in MBL deposition between
the groups (supplementary material, Figure S4). Cir-
culating neutrophil counts were the same in all groups
after GCSF treatment (supplementary material, Table
S1). These data show that both MASP-2/C3-deficient
and C3-deficient mice are protected from disease. The
phenotype of C3-deficient mice has not previously
been reported in the anti-MPO model, and these data
confirm a central role for complement in this model in
our hands.
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Figure 2. Histological and functional readouts of anti-MPO vasculitis inMASP-2-deficient mice compared with wild types. (A, B) Histological
readouts of glomerular crescents and glomerular CD68+ macrophages. (C–E) Functional readouts of serum creatinine, albuminuria, and
haematuria. At baseline, there was no haematuria detected in any of the wild-type or MASP-2-deficient mice. Each symbol represents a
separate mouse. *p< 0.05. Error bars are mean± SEM.
Evidence for increased prothrombin activation
in MASP-2-deficient mice
Previous data have shown cross-talk between MASP-2
and the coagulation pathway [30]. Since fibrin genera-
tion is an essential feature of glomerular crescent for-
mation, we wondered if the increased disease might
be explained by activation of coagulation predispos-
ing to fibrin deposition in MASP-2-deficient mice.
We confirmed this by measuring prothrombin frag-
ment 1.2, which is a breakdown product of prothrom-
bin activation and which was increased in the plasma of
untreated MASP-2 mice compared with wild type. This
provided evidence of increased prothrombin activation
(Figure 5A). We then measured residual thrombin gen-
eration in the plasma of MASP-2-deficient mice com-
pared with wild type. Figure 5B shows a typical profile
of thrombin generation over time from both a wild-type
and a MASP-2-deficient mouse. The data shown in
Figure 4C–E show that although there was no differ-
ence in the peak thrombin generation,MASP-2-deficient
mice had an increase in the lag time and a decrease in the
overall endogenous thrombin potential (ETP). No sig-
nificant difference in thrombin time or fibrinogen con-
centration was seen, but these are crude tests compared
with the sensitivity of prothrombin fragment 1.2 and
thrombin generation (Figure 5F, G). The decrease in
ETP suggested a reduction in residual thrombin gen-
eration in plasma, due to consumption of prothrom-
bin, and a situation analogous to mild disseminated
intravascular coagulation. Despite these findings, we
were unable to detect a difference in fibrin deposi-
tion in glomeruli in MASP-2-deficient compared with
wild-type mice (Figure 4 and supplementary material,
Figure S4).
Neutrophils contain intracellular C5 and C5a
In view of the emerging data on the importance of
intracellular complement components, we explored
whether neutrophils contained intracellular C5 and/or
C5a, and if so, whether this may play a role in the
development of pathology in ANCA vasculitis. We
found that small amounts of C5 and C5a were present
on the surface of non-activated neutrophils with a
small decrease in C5 expression after priming with
TNFα, followed by stimulation with fMLP, anti-MPO
or anti-PR3 ANCA (Figure 6). Intracellular C5 and
C5a were present in greater amounts and decreased
after stimulation with fMLP, anti-PR3 or anti-MPO.
We therefore measured C5a in the supernatant of
neutrophils in the absence or presence of the same acti-
vating stimuli, in serum-free conditions. Since released
C5a was likely to bind to the C5a receptor, and hence
may not be detected in the supernatant, we performed
experiments in the presence of PMX53, an antagonist
for the C5a receptor CD88. We found somewhat vari-
able results, with C5a undetectable in some donors and
levels in the range of 400–600 pg/ml in the presence
of PMX53 in others. Monocytes also express C5 and
C5a, and this is shown in the supplementary material,
Figure S5.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 61–71
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Figure 3. Histological and functional readouts of anti-MPO vasculitis in mice deficient in both MASP-2 and C3, compared with mice
deficient in C3 and wild-type mice. (A, B) Histological readouts of glomerular crescents and glomerular CD68+ macrophages. (C–E)
Functional readouts of serum creatinine, albuminuria, and haematuria. Each symbol represents a separate mouse. *p< 0.05; **p< 0.01.
Error bars are mean± SEM.
Circulating and not bone-marrow derived C5
mediates disease in anti-MPO vasculitis
We next examined if this intracellular C5a was impor-
tant in pathogenesis and constructed four groups of bone
marrow chimaeric mice from wild-type or C5-deficient
donors and recipients, and induced anti-MPO vasculi-
tis. As shown in Figure 6C, D, histological measures of
disease showed that crescentic glomerulonephritis was
more severe in both groups of C5-sufficient recipients,
compared with both groups of C5-deficient recipients,
as indicated bymore crescents and CD68+macrophages
within glomeruli. Functional readouts supported the his-
tology data, as shown in Figure 6E–G. Figure 6H shows
representative histology and CD68+ macrophage stain-
ing. Circulating neutrophil counts were the same in all
groups after GCSF treatment (supplementary material,
Table S1). These results show that the key mediator of
inflammation in anti-MPO vasculitis is C5 derived from
sources outside of the bone marrow.
Discussion
The murine anti-MPO model is an established preclin-
ical model of ANCA vasculitis. This is demonstrated
by the fact that the C5a receptor antagonist CCX168
has been tested in this model [12]. A phase II trial
(NCT01363388) has been completed with CCX168 in
patients and a second trial is underway (NCT02222155).
Haematuria and proteinuria are variable in this model,
as shown by the observation that wild-type mice had
different amounts of haematuria and proteinuria in the
experiments shown in Figures 1–3 and 6. There was also
less proteinuria in C5 deficient to wild type than in wild
type to wild-type chimaeras (Figure 6F), despite similar
histological findings and serum creatinine. In our expe-
rience, the degree of haematuria and proteinuria are not
robust markers of disease severity in individual animals
and this mirrors the situation in patients with ANCAvas-
culitis. Histological changes and serum creatinine are
therefore the primary readouts, and a lack of correla-
tion with haematuria and proteinuria, if present, would
not be a concern. Whilst others have used LPS to obtain
robust disease in this model, we also administer GCSF.
It is important to consider this when considering our
results in relation to those obtained without the addition
of GCSF.
We have made a number of observations in this model
that are of clinical relevance, given this current interest in
targeting complement in patients with ANCA vasculitis.
First, the protective role of C3 deficiency has not previ-
ously been reported in this model. Here, we have shown
for the first time that C3-deficient mice are protected. It
is important to note that we have confirmed that com-
plement is important in this model in our hands, given
the lack of protection that we saw in mice deficient in
properdin or MASP-2.
The initiator of AP activation in anti-MPO vasculi-
tis is not known, and we have excluded both properdin
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 61–71
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Figure 4. (A) Representative renal histology showing periodic acid Schiff (PAS)-stained sections and immunofluorescence staining for
CD68+macrophages frommice with anti-MPO vasculitis. The strains shown include wild types andMASP-2-, MASP-2/C3-, and C3-deficient
mice. For wild-type and MASP-2-deficient mice, MBL and fibrin deposition is also shown and there were no differences between the two
groups. Data for quantification of MBL and fibrin deposition are shown in supplementary material, Figure S5. Scale bars= 20 μm.
and the lectin pathway as candidates. Both were credi-
ble candidates. Activated neutrophils release properdin,
which has been suggested as the cause of AP activation
by neutrophils [31]. In addition to AP activation through
properdin binding to apoptotic cells [13,14], cooperation
between properdin and neutrophil-derived myeloperox-
idase may lead to AP activation [32]. The lectin pathway
was another candidate that had to be excluded because it
is a key pathway in other models of kidney inflammation
that do not require C4 [33]. Our findings are important
because they pave the way for further studies to focus on
other mechanisms of complement activation that may be
important. Previously, activation of human neutrophils
has been shown to initiate AP activation, although the
mechanism of activation was not defined [31]. It is there-
fore possible that neutrophils themselves could be cen-
tral to AP activation, perhaps via released proteases or
induced deficiencies in complement regulatory proteins.
Several such factors may combine to lead to AP activa-
tion on the surface of neutrophils or perhaps endothelial
cells, and further work will be needed to define them.
Disease in MASP-2-deficient mice was increased
compared with that in wild-type mice. In view of the
previously reported role for the AP, we wondered if
the increased disease required complement activation.
MASP-1 has been shown to activate factor D and
MASP-3 can activate factor D and factor B [34,35].
Therefore, the absence of MASP-2 could result in an
increase in MASP-1 and MASP-3 circulating in asso-
ciation with MBL and this could potentially enhance
AP activation. However, although our results in mice
deficient in both MASP-2 and C3 (Figure 2) were not
conclusive, the similarity in the levels of circulating and
deposited C3 (supplementary material, Figure S3) in
MASP-2-deficient mice compared with wild type sug-
gested that the increased disease in MASP-2-deficient
mice was not due to increased AP activation. Further-
more, wild-type and MASP-2-deficient mouse serum
samples were assessed using ELISAs specific to mouse
MASP-1 or MASP-3. The ELISAs revealed compara-
ble serum levels for MASP-1 and for MASP-3 (n= 4 per
group, data not shown).
A link between coagulation and crescentic glomeru-
lonephritis is well established. Fibrin deposition,
initiated physiologically by tissue factor, promotes
disease [36], while activation of fibrinolysis through
plasminogen activators activating plasminogen is pro-
tective [37,38]. We therefore sought an alternative
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 61–71
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Figure 5. Coagulation parameters in plasma from untreated wild-type or MASP-2-deficient mice. Each graph represents the parameter
indicated, with panel C showing typical profiles for thrombin generation over time. Each symbol represents plasma from a separate mouse.
*p< 0.05. Error bars are mean± SEM.
explanation for the increased crescent formation in
MASP-2-deficient mice and wondered if cross-talk
with the coagulation pathway could be involved. We
confirmed that MBL (and hence MASP-2) is deposited
in the glomeruli of mice with crescentic glomeru-
lonephritis, due to anti-MPO IgG as this would be a
requirement for an effect on glomerular fibrin forma-
tion. This mirrors data from a recent comprehensive
analysis of complement deposition in 187 renal biopsy
samples from patients with ANCA vasculitis [39]. This
study showed that MBL can be detected in over 30%
of cases. It may in fact be present in small quantities in
a higher proportion of cases, with detection limited by
the sensitivity of the staining method.
Activation of either the intrinsic or the extrinsic
pathways that make up the coagulation cascade leads to
the formation of a prothrombinase complex composed
of factors Va and Xa, cleaving prothrombin to thrombin.
Thrombin then activates fibrinogen, leading to the
deposition of cross-linked fibrin. Although cleavage of
prothrombin by MASP-2 has been shown to occur at the
same molecular site as factor Xa, it is far less efficient
[30]. Our data show evidence of increased prothrombin
activation in MASP-2-deficient mice compared with
wild-type mice. Therefore, a plausible explanation for
the increase in crescentic glomerulonephritis seen in
MASP-2-deficient mice is their tendency to enhanced
fibrin generation. Despite these findings in coagulation
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Figure 6. (A) Flow cytometry of isolated human neutrophils showing C5 expression, without and with cell permeabilization, in unstimulated
conditions, and after priming with TNFα followed by stimulation with monoclonal anti-MPO, anti-PR3 or fMLP. Numbers shown are median
fluorescence intensity. (B) Data under the same conditions are shown for C5a staining. Similar results (to panels A and B) were obtained in
an experiment from a different neutrophil donor. (C, D) Histological readouts of glomerular CD68+ macrophages and glomerular crescents
in anti-MPO vasculitis in four groups of bone marrow chimaeric mice constructed with wild-type or C5-deficient donors and recipients.
(E–G) Functional readouts of haematuria, albuminuria, and serum creatinine in the same experiment. For albuminuria and serum creatinine,
baseline data from the same animals are shown. Each symbol represents a separate mouse. WT=wild type, C5 Def= C5 deficient. +p< 0.05;
++p< 0.01; +++p< 0.001. (H) Representative renal histology showing periodic acid Schiff (PAS)-stained sections and immunofluorescence
staining for CD68+ macrophages from mice in this experiment. Scale bars= 20 μm. Error bars are mean± SEM.
assays, we were unable to detect a difference in fibrin
deposition in glomeruli. Whilst this may be due to
the relative insensitivity of the immunofluorescence
quantification technique used, it is equally possible
that the differences in coagulation assays did not lead
to a difference in fibrin deposition in glomeruli. The
molecular basis for the increased prothrombin activation
that we observed has not been established in this study.
Further work will be needed to establish precisely how
the absence of MASP-2, which cleaves prothrombin
relatively weakly, results in potentiation of the cleavage
of prothrombin by the prothrombinase complex.
Circulating complement components are derived
primarily from the liver, but it has recently become
clear that complement proteins are found not only
in serum and plasma but also within leukocytes.
Antigen-presenting cell-derived C3a and C5a have been
shown to augment T-cell responses [40], with important
effects relevant to transplantation and graft versus host
disease [16–18]. More recent data have shown that
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resting human CD4+ T cells contain intracellular stores
of C3 and that the protease cathepsin L cleaves C3
into C3a and C3b, with important roles described for
T-cell function and homeostasis [19–21]. Furthermore,
the balance of stimulation of the C5a receptors and
CD88 and C5L2 affects Th1 T-cell activation through
inflammasome-mediated IL-1β secretion [41] and this
may be largely due to intracellular C5a (C Kemper,
personal communication). However, despite these
developments highlighting the role of complement
components within leukocytes, our data show that
activation of C5 from other sources is important in
anti-MPO vasculitis. Since the synthesis of C5 from
murine or human renal cells has not been described, our
results demonstrate a role for circulating C5.
The present study includes several observations of
direct relevance to developing therapies in ANCA
vasculitis. We have shown that the trigger for AP acti-
vation is not the lectin pathway or the AP stabilizer
properdin, and previous work has excluded the clas-
sical pathway [9]. Therefore, future work must look
for other factors that may initiate cleavage of C3. An
ability to target the specific mechanism of complement
activation in patients may give more specificity and
potentially less toxicity than therapies aimed at C5
or C5a. However, if C5 is to be targeted in patients,
an alternative therapeutic approach to C5a receptor
blockade or an antibody to C5 such as Eculizumab
would be to prevent C5 secretion from the liver. This
would not leave intact the important homeostatic
interactions between leukocyte-derived C5a and C5a
receptors. Indeed, such an approach is being devel-
oped using N-acetylgalactosamine (GalNAc)-siRNA
conjugates to target the hepatocyte asialoglycoprotein
receptor. A phase 1–2 clinical trial in patients with
paroxysmal nocturnal haemoglobinuria is underway
(NCT02352493). The present study supports such an
approach in ANCA vasculitis as we have shown that
circulating liver-derived C5 is the key mediator of
disease.
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SUPPLEMENTARY MATERIAL ONLINE
Supplementary figure legends
Figure S1. An example of a section stained with only the secondary antibody
Figure S2. Anti-MPO levels measured in serum taken at the end of the experiment where wild-type and MASP-2-deficient mice were compared
(shown in Figure 1)
Figure S3. (A) Quantitative assessment of glomerular C3 deposition in wild-type andMASP-2-deficient mice with anti-MPO vasculitis. (B) Circulating
C3 levels in untreated wild-type and MASP-2-deficient mice
Figure S4. Quantitative assessment of glomerular fibrin and MBL deposition in wild-type and MASP-2-deficient mice with anti-MPO vasculitis
Figure S5. Intracellular staining for C5 and C5a in human blood peripheral blood monocytes
Table S1. Neutrophil counts in peripheral blood taken the day before injection of anti-MPO IgG in each of the experiments shown in this article
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